The approval of new appetite-suppressing GLP-1 weight-loss pills in the United States could trigger significant changes across the food and restaurant industry, as manufacturers prepare for shifting consumer eating habits. Analysts say the growing adoption of these medications particularly in pill form may reduce demand for certain high-calorie foods and accelerate the industry’s move toward high-protein, smaller-portion, and nutritionally targeted products.
The availability of oral formulations is expected to expand the market significantly because pills are generally cheaper and more acceptable to patients who are reluctant to use injectable treatments. GLP-1 medications, widely prescribed for weight management and diabetes, work by suppressing appetite and slowing gastric emptying, which often leads users to consume smaller meals and reduce cravings for high-sugar or high-fat foods.…
